Thursday, July 9, 2009

Innovative milieu

I've just been writing in co-work a study about science and technology policy, referring to its opportunities and performances on higher education. It is in tight connection with innovation and research and development processes and theories. Ultimately, with the economic growth theories. Nowadays there is a broadly accepted, consencual view that the knowledge based society can be the best way to subdue the fiercy global competition.

After "Capitalism, Socialism, and Democracy"


Once upon a time, the writer of "Capitalism, Socialism and Democracy" entitled book, Joseph A. Schumpeter said that the innovation is important and can trigger / just for You ;-) / the potential growth rates. In order to some way we get us to be innovative, and have innovative milieu we have lots of formations, and incentives method.

Numerous researcher's study suggest that we have to concentrate our resources, and estabilish business networks and clusters with higher education systems.

For a long time, the applied and basic research works did'nt get the right emphases, but now, the European Union has revealed its programs, and the resented lack of basic research's focus will be more important in the future.

Specific example


European Cancer Cluster (ECC) Partnering 2009 event

The Cancer-Bio-Health Cluster and the Oslo Cancer Cluster are organising the European Cancer Cluster (ECC) Partnering 2009 event to take place on 3 and 4 September in Toulouse, France.

The event will bring together business representatives, investors and scientists from the fields of diagnostics, therapeutics, drug delivery, medical devices and medical imaging.

Keynote speeches, presentations and discussion roundtables will address such topics as:
- evaluating the oncology industry;
- building partnerships with investors;
- the Innovative Medicines Initiative (IMI).

Beyond that, the aim is to build a 'Europe of the cancer clusters' and to support companies, spin-offs, small and medium sized enterprises (SMEs) and large pharmaceutical enterprises in building new partnerships.

For further information, please visit this.